Literature DB >> 2604741

Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs--1. In vitro studies of ibuprofen and flurbiprofen.

R D Knihinicki1, K M Williams, R O Day.   

Abstract

The mechanism of inversion of the enantiomers of 2-arylpropionic acids was investigated in vitro using tissue homogenates. Crude rat liver homogenate was shown to mediate the inversion of R to S-ibuprofen, but not inversion of the S to the R-enantiomer. Inversion required CoA and ATP as cofactors. In contrast, R-ibuprofen was not inverted by homogenates of kidney or small intestine and there was no inversion of the enantiomers of flurbiprofen by any of these tissue homogenates. Long-chain acyl-CoA synthetase was partially purified from rat liver microsomes and bound to Matrex Gel Red A. R-Ibuprofen was shown to be a substrate for this enzyme while S-ibuprofen and R and S-flurbiprofen were not substrates. These data are consistent with the hypothesis that the stereospecificity of inversion is controlled by the acyl-CoA synthetase. R-Ibuprofen-CoA did not racemize in either buffer solution (pH 7.4) or human plasma consistent with the hypothesis that racemization of the CoA thioesters is mediated enzymatically.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2604741     DOI: 10.1016/0006-2952(89)90647-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

Review 1.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Stereoselective disposition of flurbiprofen in uraemic patients.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

3.  Stereoselective disposition of flurbiprofen in normal volunteers.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

4.  Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid Moiety.

Authors:  Shuwen He; Qingmei Hong; Zhong Lai; Zhicai Wu; Yang Yu; David W Kim; Pauline C Ting; Jeffrey T Kuethe; Ginger X Yang; Tianying Jian; Jian Liu; Deodial Guiadeen; Arto D Krikorian; Donald M Sperbeck; Lisa M Sonatore; Judyann Wiltsie; Christine C Chung; Jack T Gibson; JeanMarie Lisnock; Beth A Murphy; Judith N Gorski; Jinqi Liu; Dunlu Chen; Xiaoli Chen; Michael Wolff; Sharon X Tong; Maria Madeira; Bindhu V Karanam; Dong-Ming Shen; James M Balkovec; Shirly Pinto; Ravi P Nargund; Robert J DeVita
Journal:  ACS Med Chem Lett       Date:  2013-06-06       Impact factor: 4.345

Review 5.  Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use.

Authors:  J Cashman; G McAnulty
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

6.  Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations.

Authors:  G Li; G Treiber; K Maier; S Walker; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Renal handling and effects of S(+)-ibuprofen and R(-)-ibuprofen in the rat isolated perfused kidney.

Authors:  P G Cox; W M Moons; F G Russel; C A van Ginneken
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

8.  Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.

Authors:  H Cheng; J D Rogers; J L Demetriades; S D Holland; J R Seibold; E Depuy
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

9.  Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro.

Authors:  M Villanueva; R Heckenberger; H Strobach; M Palmér; K Schrör
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

10.  Chiral separation of ibuprofen and chiral pharmacokinetics in healthy Chinese volunteers.

Authors:  Chaonan Zheng; Haiping Hao; Guangji Wang; Guowei Sang; Jianguo Sun; Peng Li; Jing Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.